CureVac N.V. Stock Forecast for 2023 - 2025 - 2030
Updated on 04/23/2024
CureVac N.V. Stock Forecast and Price Target
The average price target for CureVac N.V.'s stock lately set by several renowned analysts is $12.73, which would result in a potential upside of approximately 389.62% if it reaches this mark by December 31, 2024. This estimation is based on a high estimate of $16.62 and a low estimate of $2.74. If you're interested in investing in this company, why not also look at its competitors to see how they are doing?
389.62% Upside
CureVac N.V. Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Price for CureVac N.V. has grown by 100.00%, going from $0.00 to $0.00. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach $0.00 – an increase of 100.00%. Over the next six years, experts anticipate that Fair Value growth for CureVac N.V. will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TMO Stock Forecast | Thermo Fisher Scientific | Outperform |
10
|
$574.59 | Buy/Sell | $591.94 | 5.55% |
| DHR Stock Forecast | Danaher | Outperform |
10
|
$253.11 | Buy/Sell | $260.33 | 6.67% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$26.32 | Buy/Sell | $32.87 | 15.88% |
| SAN Stock Forecast | Sanofi | Outperform |
16
|
88.85€ | Buy/Sell | 102.80€ | 21.55% |
| GSK Stock Forecast | GSK | Outperform |
12
|
£16.51 | Buy/Sell | £17.30 | 18.11% |
CureVac N.V. Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Revenue for CureVac N.V. has grown by 37.96%, going from $48.87M to $67.42M. In the coming year, analysts are expecting an increase in Revenue, predicting it will reach $79.32M – an increase of 17.66%. Over the next eight years, experts anticipate that Revenue growth for CureVac N.V. will be 19.75%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MRNA Stock Forecast | Moderna | Outperform |
16
|
$107.89 | Buy/Sell | $135.42 | 15.30% |
| BNTX Stock Forecast | BioNTech | Outperform |
12
|
$88.49 | Buy/Sell | $123.75 | 13.62% |
| 1548 Stock Forecast | Genscript Biotech | Buy |
5
|
HK$10.98 | Buy/Sell | HK$3.96 | -65.03% |
.jpg)
CureVac N.V. EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, CureVac N.V.'s EBITDA has grown, increasing from $-127.73M to $-209.60M – an increase of 64.10%. For next year, the 0 analysts predict EBITDA of $-689.23M, which would mean an increase of 228.83%. Over the next eight years, the pros' prediction is EBITDAof $-1.54B, which would mean a eight-year growth forecast of 634.84%.
CureVac N.V. EBIT Forecast for 2023 - 2025 - 2030
CureVac N.V.'s EBIT has increased by 69.48% In the last two years, going from $-133.55M to $-226.34M. In the next year, analysts expect EBIT to reach $-696.67M – an increase of 207.80%. For the next eight years, the forecast is for EBIT to grow by 529.66%.
CureVac N.V. EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, EPS for CureVac N.V. has grown by 100.00%, going from $-0.98 to $0.00. In the coming year, analysts are expecting an increase in EPS, predicting it will reach $0.00 – an increase of 100.00%. Over the next six years, experts anticipate that EPS growth for CureVac N.V. will be 100.00%.
.jpg)